Last reviewed · How we verify
Fundación Universitaria de Ciencias de la Salud — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Remifentanil Laboratorios Chalver de Colombia S.A. | Remifentanil Laboratorios Chalver de Colombia S.A. | marketed | ||||
| Remifentanyl, Ultiva® | Remifentanyl, Ultiva® | marketed | Opioid agonist | Mu (μ) opioid receptor | Anesthesia | |
| Fada Remifentanilo | Fada Remifentanilo | marketed | Opioid agonist | Mu (μ) opioid receptor | Anesthesia and Pain Management |
Therapeutic area mix
- Anesthesia · 1
- Anesthesia and Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ain Shams University · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Beijing Friendship Hospital · 1 shared drug class
- Cephalon · 1 shared drug class
- Ciusss de L'Est de l'Île de Montréal · 1 shared drug class
- Corporacion Parc Tauli · 1 shared drug class
- Eastern Maine Medical Center · 1 shared drug class
- Aarhus University Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Fundación Universitaria de Ciencias de la Salud:
- Fundación Universitaria de Ciencias de la Salud pipeline updates — RSS
- Fundación Universitaria de Ciencias de la Salud pipeline updates — Atom
- Fundación Universitaria de Ciencias de la Salud pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Fundación Universitaria de Ciencias de la Salud — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-universitaria-de-ciencias-de-la-salud. Accessed 2026-05-17.